Recombinant antibodies for treatment of respiratory syncytial virus infections

US7879329B2 · kind B2 · utility

Assignee

• Symphogen A/S · DK

Inventors

• Johan Lantto · Lund, SE
• Henriette Schjønning Nielsen

Key dates

• Filing date: Mar 6, 2008
• Grant date: Feb 1, 2011
• Expiry date: Mar 6, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18511
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are novel polyclonal antibodies, which target respiratory syncytial virus (RSV), as well as novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The antibody molecules of the invention have shown superior efficacy in vitro and/or in vivo. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment or prevention of RSV infection.